Amgen (AMGN) Receivables (2009 - 2026)
Amgen (AMGN) posted quarterly Receivables of $9.1 billion for Q1 2026, up 12.37% year-over-year from $8.1 billion in Q1 2025, and down 4.51% quarter-over-quarter from $9.6 billion in Q4 2025.
Amgen (AMGN) Receivables (2009 - 2026) Analysis & Trends
Amgen's Receivables history runs 18 years deep, the most recent figure standing at $9.1 billion for Q1 2026.
- In Q1 2026, Receivables rose 12.37% year-over-year to $9.1 billion; the TTM figure through Mar 2026 stood at $9.1 billion (up 12.37% YoY), while the FY2025 annual figure was $9.6 billion, up 37.11% from the prior year.
- Receivables for Q1 2026 stood at $9.1 billion, down from $9.6 billion in the prior quarter.
- The five-year high for Receivables was $9.6 billion in Q4 2025, with the low at $5.1 billion in Q1 2022.
- The 5-year median for Receivables is $6.9 billion (2024), against an average of $7.0 billion.
- The sharpest annual moves came in 2024 and 2025: Receivables fell 10.17% in 2024, then surged 37.11% in 2025.
- Amgen's Receivables stood at $6.3 billion in 2022, then climbed by 24.06% to $7.8 billion in 2023, then fell by 10.17% to $7.0 billion in 2024, then soared by 37.11% to $9.6 billion in 2025, then dropped by 4.51% to $9.1 billion in 2026.
- Business Quant data shows AMGN's Receivables at $9.1 billion in Q1 2026, $9.6 billion in Q4 2025, and $8.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.90 Bn | 629.14 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 467.27 Bn | 460.70 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 376.18 Bn | 369.04 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 300.31 Bn | 292.62 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 256.63 Bn | 251.73 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 235.80 Bn | 221.81 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 160.71 Bn | 149.01 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 105.41 Bn | 101.24 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 54.87 Bn | 47.49 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.23 Bn |
| Mar 31, 2026 | 9.14 Bn |
| Dec 31, 2025 | 9.57 Bn |
| Sep 30, 2025 | 8.49 Bn |
| Jun 30, 2025 | 8.70 Bn |
| Mar 31, 2025 | 8.13 Bn |
| Dec 31, 2024 | 6.98 Bn |
| Sep 30, 2024 | 7.32 Bn |
| Jun 30, 2024 | 6.93 Bn |
| Mar 31, 2024 | 6.78 Bn |
| Dec 31, 2023 | 7.77 Bn |
| Sep 30, 2023 | 6.15 Bn |
| Jun 30, 2023 | 5.83 Bn |
| Mar 31, 2023 | 5.74 Bn |
| Dec 31, 2022 | 6.26 Bn |
| Sep 30, 2022 | 5.33 Bn |
| Jun 30, 2022 | 5.33 Bn |
| Mar 31, 2022 | 5.08 Bn |
| Dec 31, 2021 | 5.06 Bn |
| Sep 30, 2021 | 4.77 Bn |